Gilead Sciences (GILD) Non Operating Income (2009 - 2026)

Gilead Sciences (GILD) has reported Non Operating Income for 18 consecutive years, with $387.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Income rose 86.06% year-over-year to $387.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.5 billion (up 919.87% YoY), and the FY2025 full-year result was $798.0 million, up 13200.0% from the prior year.
• Non Operating Income grew to $387.0 million in Q2 2026 per GILD's latest filing, from $235.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at $569.0 million in Q3 2025 and bottomed at -$355.0 million in Q2 2024.
• Historically, Non Operating Income has averaged $58.1 million across 5 years, with a median of $40.5 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Non Operating Income soared 3030.0% in 2023, then plunged 460.44% in 2025.
• Over 5 years, Non Operating Income stood at -$10.0 million in 2022, then jumped by 3030.0% to $293.0 million in 2023, then slumped by 111.95% to -$35.0 million in 2024, then soared by 1097.14% to $349.0 million in 2025, then advanced by 10.89% to $387.0 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $387.0 million, $235.0 million, and $349.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.